Frank J. Brescia
Expertise in
8
conditions

Dr. Frank J. Brescia

Oncology
86 Jonathan Lucas St, 
Charleston, SC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
8
conditions
86 Jonathan Lucas St, 
Charleston, SC 

Overview

Frank Brescia, MD, MA, specializes in Breast Cancer, and Medical Oncology and is located in Charleston, SC.

Dr. Brescia is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Angiosarcoma, Inflammatory Breast Cancer, and Paget Disease of the Breast.

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 13 clinical trials. Dr. Brescia is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in SC

Hospital Affiliations

Tidelands Waccamaw Community Hospital
Musc Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

MUSC Hollings Cancer Center
86 Jonathan Lucas St, Charleston, SC 29425
Other Locations
MUSC Hollings Cancer Center
86 Jonathan Lucas St, Charleston, SC 29425

Additional Areas of Focus

Dr. Brescia has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Breast Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Drug
Study Drug: Carvedilol
Study Phase: Phase 3
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Other, Procedure
Study Phase: Phase 2
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: June 01, 2026
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: May 29, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer
Enrollment Status: Completed
Publish Date: May 19, 2026
Intervention Type: Drug
Study Drug: Bupropion Hydrochloride
Study Phase: Phase 2
Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women
Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2026
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Paclitaxel
Study Phase: Phase 2
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: April 29, 2026
Intervention Type: Other, Drug
Study Drugs: Palbociclib, Letrozole, Fulvestrant
Study Phase: Phase 2
Evaluation of Mammographic Breast Density Effect of Aspirin: a Companion Study to Alliance Study A011502
Evaluation of Mammographic Breast Density Effect of Aspirin: a Companion Study to Alliance Study A011502
Enrollment Status: Terminated
Publish Date: January 16, 2025
Intervention Type: Procedure
View 9 Less Clinical Trials

2 Total Publications

Rechallenge of an alternative CDK 4/6 inhibitor after hepatotoxicity in the treatment of hormone-positive metastatic breast cancer.
Rechallenge of an alternative CDK 4/6 inhibitor after hepatotoxicity in the treatment of hormone-positive metastatic breast cancer.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: May 13, 2025
Similar Doctors
Expertise in
44
conditions
Expertise in
44
conditions
Referral may be required

MUSC University Hospital

171 Ashley Ave, 
Charleston, SC 
 (0.1 miles away)
843-792-2300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Lindhorst is an Oncologist practicing medicine in Charleston, South Carolina. Dr. Lindhorst is highly rated in 44 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, Brain Tumor, and Awake Craniotomy.

Expertise in
37
conditions
Dr. Robert Stuart
Hematology | Oncology
Expertise in
37
conditions
Dr. Robert Stuart
Hematology | Oncology
Referral may be required

MUSC University Hospital

171 Ashley Ave, 
Charleston, SC 
 (0.1 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances

Robert Stuart is a Hematologist and an Oncologist practicing medicine in Charleston, South Carolina. Dr. Stuart is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
29
conditions
Dr. Irl Greenwell
Hematology | Oncology
Expertise in
29
conditions
Dr. Irl Greenwell
Hematology | Oncology
Referral may be required

Charleston Hematology Oncology Associates PA

2085 Henry Tecklenburg Dr Fl 2, 
Charleston, SC 
 (5.7 miles away)
843-577-6957
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Irl Greenwell is a Hematologist and an Oncologist practicing medicine in Charleston, South Carolina. Dr. Greenwell is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Reticulohistiocytoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Frank J. Brescia

How do I make an appointment with Dr. Frank J. Brescia?

You can book an appointment with Dr. Frank J. Brescia by calling their office at 843-792-9300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Frank J. Brescia a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Frank J. Brescia is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Frank J. Brescia specialize in?

While Dr. Frank J. Brescia is a Oncology, they have specific expertise in Breast Cancer, Angiosarcoma, and Inflammatory Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Frank J. Brescia participate in research or clinical trials?

Yes. Dr. Frank J. Brescia has published 2 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Frank J. Brescia's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Frank J. Brescia accept my insurance?

Dr. Frank J. Brescia accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly at 843-792-9300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Brescia's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile